Cerevel Therapeutics CEO on going public through a SPAC

In the latest of dozens of SPACs to IPO, Cerevel Therapeutics has debuted on the public markets in a transaction well over $400 million. The company spun off from Pfizer two years ago and now focuses on neuroscience research. Dr. Tony Coles, chairman and CEO of Cerevel Therapeutics and board member at Regeneron, joins "Squawk Box" to discuss.
03:27
Fri, Jul 31 20208:18 AM EDT